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Preamble 
The following clinical spotlight review regarding Transanal Minimally Invasive Surgery (TAMIS) is 
intended for physicians who manage and treat rectal pathology. It is meant to critically review this 
technique and the available evidence supporting its safety and efficacy. Based on the level of evidence, 
recommendations may or may not be given for its use in clinical practice. 
Disclaimer 
Guidelines for clinical practice and spotlight reviews are intended to indicate preferable approaches to 
medical problems as established by experts in the field. These recommendations will be based on 
existing data or a consensus of expert opinion when little or no data are available. Spotlight reviews are 
applicable to all physicians who address the clinical problem(s) without regard to specialty training or 
interests, and are intended to convey recommendations based on a focused topic; within the defined 
scope of the review, they indicate the preferable, but not necessarily the only acceptable approaches 
due to the complexity of the healthcare environment. Guidelines and recommendations are intended to 
be flexible. Given the wide range of specifics in any healthcare problem, the surgeon must always 
choose the course best suited to the individual patient and the variables in existence at the moment of 
decision. Guidelines, spotlight reviews, and recommendations are developed under the auspices of the 
Society of American Gastrointestinal Endoscopic Surgeons and its various committees, and approved by 
the Board of Governors. Each clinical spotlight review has been systematically researched, reviewed and 
revised by the guidelines committee, and, when appropriate, reviewed by an appropriate 
multidisciplinary team. The recommendations are therefore considered valid at the time of production 
based on the data available. 
Literature review 
A systematic literature search was performed using PubMed for Transanal Minimally Invasive Surgery 
(TAMIS). The literature was reviewed from September 1, 2010 through May 31, 2016. 
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Transanal minimally invasive surgery (TAMIS) is a technique that was originally devised as a hybrid 
between Transanal Endoscopic Microsurgery (TEM) and single-site laparoscopy for resection of rectal 
lesions. It was developed out of the need for a practical alternative to TEM that was both affordable and 
technically feasible without specialized equipment. TEM, introduced over 30 years ago by Dr. Gerhard 
Buess,3-8 has demonstrated to be superior to standard transanal excision for treating  benign and 
malignant rectal lesions, most notably due to its ability to perform high-quality resections with 
decreased incidence of fragmentation.9,10 The benefit is likely due to the quality optics, instruments, and 
specialized insufflation system. Despite its feasibility and efficacy, the widespread implementation of 
TEM has been prevented by several barriers, mostly attributable to its steep learning curve and 
expensive equipment.11-13 Because of this, the optimal method for removal of lesions of the mid and 
upper rectum remains controversial. Patients are referred to specialized centers performing TEM or are 
subjected to more radical surgery such as a low anterior resection (LAR) or abdominoperineal resection 
(APR).  First described in 2010,14 TAMIS is based on a platform that is readily available in most hospitals, 
bringing access for more proximal rectal lesions to any minimally invasive surgeon with a clear 
knowledge and understanding of rectal pathology, anatomy, and surgery.  It is categorized by the use of 
a single-site port transanally in combination with ordinary laparoscopic instruments, a laparoscopic 
camera lens, and a standard laparoscopic CO2 insufflator for the purpose of performing endoluminal 
rectal surgery. 
Literature suggests that the TEM approach allows for more intact, non-fragmented specimens (100% vs. 
63%), negative resection margins (98% vs. 78%), and lower recurrence rates (8% vs. 24%) than standard 
transanal excision.10 Similar results have been presented with TAMIS, with a 4% fragmentation rate, 6% 
microscopic margin positivity and a 2% recurrence rate.15 There are several data comparing TEM to 
standard transanal excision and to radical intra-abdominal approaches but a paucity of publications 
comparing TEM and TAMIS. An ex vivo study  grading surgeons not trained in transanal techniques 
showed similar scores for completing an adequate dissection using both TEM and TAMIS equipment.16 
Some of the advantages of TAMIS over TEM include rapid set-up time, 360 degrees vs. 220 degrees of 
visibility within the rectal lumen, the ability to universally adapt any existing laparoscopic instruments in 
the hospital, and the ease of lithotomy positioning within the operating theatre.14,17-24 The initial 
description of the procedure reported a set-up time as rapid as 2 minutes.14 This greatly reduces the 
total operative time when compared to TEM, which can have set up times as long as 30-45 minutes if 
the lesion is in an inconvenient position. The cost of the single-use ports used for TAMIS is nearly 
equivalent to the cost of the specialized disposable CO2 tubing required for each TEM case.14,18 Similar to 
TEM, 14,25-27 TAMIS also results in minimal anal sphincter dysfunction.68,69  
 
II. Statement of focus 
 
The intent of this clinical spotlight review is to critically review literature related to TAMIS, including the 
indications, setup and equipment, technical aspects, and clinical outcomes of the procedure.  
 
III. Pre-Operative Workup and Patient Selection for Rectal Masses 
 
A. Pre-Operative Workup 
 If a rectal lesion is identified on digital rectal exam, a full colonoscopy should be performed to rule out 
any synchronous lesions and to biopsy the rectal mass. A detailed physical examination should be 
documented including digital rectal exam and rigid proctoscopy noting the size, distance from the anal 
verge and anorectal junction, and positional orientation of the lesion. Careful attention should be paid 
to whether the tumor is soft or firm, mobile or fixed. If the biopsy returns as a malignant lesion, further 
workup for accurate staging should be performed using rectal MRI or Endorectal ultrasound (EUS). 
Which modality to use depends on institutional availability and expertise, but using one or both is 
acceptable.28,29  CT of the chest, abdomen, and pelvis are also ordered to rule out metastatic disease 
along with routine laboratory investigations, including carcinoembryonic antigen (CEA) levels, and 
molecular tumor markers according to National Comprehensive Cancer Network (NCCN) Guidelines.30  
B. Patient Selection 
The indications for TAMIS are similar to TEM and standard transanal resection for benign and malignant 
lesions determined by EUS or MRI.31-33 For malignant masses, TAMIS is generally appropriate for patients 
with early rectal cancer, which is defined as invasive adenocarcinoma confined to the submucosal layer, 




 This can be further categorized into low-risk T1 adenocarcinomas of the rectum, which are characterized 
as small (< 4 cm), well differentiated tumors without lymphatic, vascular or perineural involvement.35 
For patients with poor histologic features (lymphovascular or perineural invasion, poor differentiation, 
tumor budding), discussion at a multi-disciplinary tumor board should ensue to reach a consensus on 
subsequent treatment. T1 cancers with deeper submucosal invasion (sm2 or sm3) as determined by the 
Kikuchi classification of sessile lesions may confer metastatic potential to lymph nodes and should 
essentially be treated as a T2 lesion.36,37   
 
Image 1   Depth of submucosal invasion: submucosa divided into thirds according to Kikuchi classification  
For indeterminate T1 versus T2 lesions with no evidence of nodal disease, a TAMIS resection can serve 
as definitive biopsy confirming T stage and guiding further treatment with the final pathology. These 
patients should be counseled preoperatively that if the pathology returns as a T1 lesion with favorable 
pathologic characteristics, they would have undergone a curative-intent surgery with no need for 
further intervention. If the pathology returns as T1 with adverse pathologic features (including deeper 
submucosal invasion) or a T2 lesion, they may still need a formal radical resection (in the form of an LAR 
or APR) or adjuvant chemotherapy and radiation. Borschitz and colleagues38 reported a 12% local 
recurrence after immediate reoperation vs 35% recurrence for those who underwent TEM alone for T2 
cancers. Several other reports determined comparable oncologic outcomes for immediate reoperation 
after local excision compared to primary radical resection.39,40 In a study by Dudek in 2008, 41 the most 
favorable outcomes were in those pT2 lesions resected with negative margins that went on to receive 
adjuvant radiotherapy; all 12 of the patients were disease-free after a median follow-up of 3 years. 
Conversely, patients with uT2 lesions may be down staged with preoperative chemotherapy and 
radiation prior to TAMIS resection. In a few studies this has led to promising results,42,43 including a 
number of patients that developed complete pathologic response.44,45 The most impressive results have 
come from Habr-Gama and Perez, with up to 44% complete response utilizing their protocol for 
neoadjuvant chemo-radiotherapy.46 This unquestionably needs longer term follow-up before it can 
become standard protocol.  
Advanced lesions (T3) can be considered for TAMIS resection when patients are deemed medically unfit 
to have a more radical surgery. Patients found to have nodal disease or distant metastases should be 
evaluated by a multidisciplinary tumor board where available and considered for chemotherapy and 
radiation prior to surgical resection.  The indications for TAMIS can also be broadened to include local 
excision of clinical T0 (cT0) lesions in patients with locally advanced rectal cancer after neoadjuvant 
therapy for the purpose of confirming mural complete pathologic response (cPR) or ypT0.47-49 This 
approach is acceptable given that the risk of occult node positivity for ypT0 lesions is predictably low, at 
3-6%.50-52 The discussion with the patient should highlight the benefits and risks of preservation of rectal 
function and avoiding functional consequences of a pelvic dissection with the understanding that they 
still need close follow-up postoperatively. 
Though there are limited data evaluating the effectiveness of TAMIS for resection of carcinoid tumors, it 
seems a likely alternative for removing small rectal carcinoids either primarily or after incomplete 
endoscopic removal.72,80 Several studies from the TEM data show that these are usually smaller lesions 
and less challenging than rectal adenocarcinomas.73 These authors report no positive margins in their 
final surgical specimens and no local recurrence.71-76 In the TAMIS data, similar results are noted in 
recurrence rates after TAMIS excision for rectal carcinoids, with no recurrences at 9.8 months of follow 
up.27   
 
IV. Operative Technique 
 
A.  Surgical Preparation 
Standard perioperative protocols for colorectal surgery should be followed, including perioperative 
antibiotics, beta blockers and DVT prophylaxis. A bowel preparation is needed but the type can be left 
up to the surgeon’s preference. 53 Some may prefer to have their patients perform a full mechanical 
bowel preparation,54,55 but a flexible sigmoidoscopy preparation (dose of oral laxative and 2 enemas) is 
more than adequate for visualization in most patients. The complication of colonic gas explosion has not 
been encountered, most likely due to the fact that CO2 is used for insufflation and that the smoke, and 
therefore methane gas, is vented during the procedure. 
Lithotomy position can be used in all patients regardless of the lesion location. This expedites set up 
time in the operating room and is preferred by most anesthesiologists.  Alternative positions such as 
prone jack-knife or lateral decubitus have also been described. The prone jack-knife position can be 
considered for anterior based lesions, although the disadvantage of having to reposition the patient in 
the case of peritoneal entry has to be considered.53-56 Candy cane or Allen stirrups may be used based 
on their availability. If there is any question that abdominal access may be required such as anticipated 
peritoneal entry for anterior proximal lesions, Allen stirrups are preferred so that the legs may be 
repositioned for the abdominal portion of the procedure. Patients should be low on the table to enable 
transanal access, and the stirrups should be high enough to prevent encroachment on the surgeon’s 
working space. Trendelenburg position can be added if needed. A video monitor placed over the 
abdomen between the patient’s legs provides the most ergonomic position for the surgeon and 
assistant. Patients can then be prepped and draped in the normal fashion. If peritoneal entry is 






B.  Set up and equipment 
In the US, there are currently two FDA approved devices for transanal access for the TAMIS procedure-- 
the GelPOINT Path (Applied Medical, Rancho Santa Margarita, CA) and the SILS™ Port (Covidien, 
Mansfield, MA). Both are easily placed transanally and allow insufflation through a separate channel. 
The GelPOINT Path also has a channel for smoke evacuation to maintain clear visualization throughout 
the procedure. The remaining equipment is standard instrumentation found in the operating room, 
usually in a rectal tray and a laparoscopic cholecystectomy tray. Pneumorectum is achieved using a 
typical laparoscopic tower with CO2 for insufflation. Initial pressure settings should be between 8-18 
mmHg and can be increased if there is difficulty maintaining distention of the rectum for visualization. 
Recently the use of the AirSeal® insufflator has been described to create and maintain pneumorectum.57 
This provides continuous high flow insufflation, pressure sensing and smoke evacuation and may prove 
to be a promising addition to the equipment given that the rectum presents such a confined 
environment. General anesthesia with muscle paralysis is recommended to avoid collapse of the rectal 
wall which can occur with diaphragmatic breathing.  TAMIS has been described using spinal anesthetic 
successfully as well.27 Routine placement of a Foley catheter can be considered.55 
A 30 or 45-degree angled laparoscope,55,56 ideally with inline or right angled optical cables, is preferred 
during dissection over 0-degree scopes. Bariatric length laparoscopes can also be used to prevent 
instrument conflicts. Alternatively, a colonoscope or flexible tipped scopes have also been described for 
visualization.53,54  Maryland graspers, or similar, may be used for retraction. Monopolar electrosurgery is 
generally adequate for dissection. This can be connected to a standard suction irrigator to facilitate 
suctioning of fluid or smoke during the procedure.  More advanced bipolar devices can also be used but 
will add expense to the procedure. These are excessive for a submucosal dissection but may be better 
suited for a full-thickness resection.  
Closure of the defect, when necessary, is accomplished with simple laparoscopic suturing techniques 
using standard needle drivers or with more advanced laparoscopic closure devices based on the 
surgeon’s preference. These devices may be more expensive but may decrease the operative time.  
 
C.  Technical considerations 
Standard principles used in transanal resection or TEM resection of lesions should be followed for a 
TAMIS resection as well. It is recommended that the lesion be marked around its circumference to 
ensure an adequate margin prior to beginning the dissection. Benign lesions such as adenomas may be 
excised in the submucosal plane with negative margins. Because these are not full-thickness defects, 
they do not necessarily need to be closed. For malignant lesions, a 1 cm margin should be marked out 
around the entire mass prior to a full-thickness resection.38 It is of utmost importance to remain 
perpendicular to the tumor so as not to compromise the deep margin.  
For posterior tumors, a small cuff of perirectal fat can be excised with the specimen to ensure full 
thickness excision and allow pathologic evaluation of lymph nodes in the immediate area.58 Care must 
be taken not to disrupt the mesorectal envelope so that if unfavorable pathology is discovered 
unexpectedly, a rescue TME can still be performed without violating oncologic principles. CO2 
insufflation can provide a natural ‘pneumo-dissection’ which helps expose the planes of dissection.14,54   
Closure of the defect is one of the more time-consuming portions of the procedure. Submucosal 
resections can be left open. Full thickness defects can technically be left open as they are extra-
peritoneal;53 however, it is generally recommended to close all defects so that if a peritoneal entry does 
occur, the necessary skills to close the defect have been practiced.56 Defects are closed transversely so 
as not to narrow the lumen of the rectum8 and can be done with a running stitch or with multiple figure-
of-eight stitches. It is more difficult to tie intracorporal knots within the limited confines of the rectal 
lumen. To overcome this, intraluminal knot-tying can be accomplished with the use of a knot-pusher or 
laparoscopic suture clips. Laparoscopic suturing devices also speed up this process, decreasing operative 
times. For patients with prior radiation, a higher incidence of wound dehiscence is sometimes noted.59  
Evidence shows lesions located anteriorly in the middle or upper third of the rectum carry a higher risk 
of peritoneal entry, likely owing to a lower peritoneal reflection on the anterior and lateral surfaces of 
the rectum.62 If intraperitoneal entry does take place, the patient should be placed in steep 
Trendelenburg position to allow the abdominal contents to fall out of the pelvis.  Though many 
peritoneal entries can be closed via the TAMIS port, it can sometimes be difficult to maintain 
pneumorectum and adequate visualization with a defect into the peritoneal cavity.  In this instance, 
converting to a laparoscopic assisted approach to aid in closure of the defect should not be 
delayed.56,60,61 Some authors recommend placing patients in the prone position if peritoneal entry is 
likely, where the pressure on the abdomen limits the amount of insufflation that can traverse into the 
peritoneal cavity.81 A Gastrografin enema can be considered prior to discharge to ensure that there is 
not a leak after repair. 
For very distal lesions at or just above the dentate line, a hybrid approach with standard transanal and 
TAMIS equipment can facilitate resection.77 The distal margin is incised using standard transanal 
retractors from the hemorrhoidectomy tray and electrosugery. The TAMIS port can then be inserted to 
use for the remainder of the proximal dissection. This allows for better visualization of the proximal 
extent of the tumor and less fragmentation of the specimen. Closing a distal defect is easier, as a single 
stitch can be placed on the proximal edge in the midline of the excision site and used to reapproximate 
to the distal edge via standard transanal approach.62 
 
V.  Postoperative Care and Follow-up 
 
TAMIS is generally viewed as an outpatient procedure and most patients are discharged on the day of 
surgery. Depending on comorbidities, the option to admit for 23-hour observation with discharge on the 
first post-operative day is also reasonable. Diets can be advanced as tolerated without restrictions. If a 
full-thickness resection was undertaken or intra-peritoneal entry occurred, SCIP protocol requires 
antibiotic coverage for 24 hours postoperatively. Those that use pre-operative ertapenem have no need 
for repeat dosing. Patients can be transitioned to oral antibiotics with anaerobic and gram negative 
coverage for a period of seven days if there is concern for local infection. 
Standard postoperative follow-up is generally performed at two and six weeks. Rigid proctoscopy is part 
of the clinical exam to assess healing. Patients with malignant lesions who underwent a satisfactory 
TAMIS excision are followed according to National Comprehensive Cancer Network guidelines 
depending on final pathology. For patients with excised specimens that reveal more advanced disease or 
histologically unfavorable features, discussion at a multidisciplinary tumor board should ensue. The 
options for further treatment may include standard oncologic resection or postoperative chemotherapy 
and radiation.30  
 
VI. Clinical outcomes 
 
In a systematic review of the literature that was published in 2014, thirty-three retrospective studies 
and case reports representing 390 TAMIS procedures published between 2009 and 2014 were 
reviewed.62 The average size of the lesions resected was 3.1 cm (range 0.8-4.75 cm) and the mean 
distance from the anal verge was 7.6 cm (range 3-15 cm). Margin status was described in 25 out of the 
33 publications (n=275 patients) and 12 specimens were reported as having positive margins (12/275, 
4.36%). Similarly specimen fragmentation was reported in 10 of 22 publications (n=97 patients) and was 
approximately 4%. Being a relatively new technique, there is limited follow-up data. The recurrence rate 
after excision of benign and malignant lesions was reported in 16 publications (n=259) and was 2.7% 
(7/259) with a 7.1 month follow-up. Of all the published studies in this review, only 8 had 15 or more 
patients.  
One of the largest published series in this review was by Albert and Atallah and included 50 patients (25 
benign neoplasms, 23 malignant lesions, and 2 neuroendocrine tumors). In this study with a 20-month 
follow-up, the overall locoregional recurrence rate was 4.3%. Positive margins were demonstrated in 6% 
of the specimens.15 A more recent series by Keller and Haas outlines 75 patients (59 benign, 17 
malignant lesions) with a median follow-up of 39.5 months. Positive margins were equivalent in 6.6% of 
patients and only one patient developed recurrence at the conclusion of the review period. Three 
patients had intraperitoneal entry and all were able to be closed transanally.77 
Postoperative complications associated with TAMIS include general complications associated with 
surgery as well as specific complications related to anorectal procedures. General morbidity include 
infectious (fever, urinary tract infections, C. difficile colitis) and cardiopulmonary (atrial fibrillation, COPD 
exacerbation) complications. Procedure specific complications include bleeding, urinary retention, 
extraperitoneal wound dehiscence, rectal stenosis and transient fecal incontinence.62 Peritoneal entry is 
a known complication of this technique and is more likely to occur with lesions that are anterior and 
located in the proximal one-third of the rectum. Based on extensive TEM experience, there are no data 
to suggest that full-thickness excision of rectal tumors and peritoneal entry is associated with 
postoperative complications.78,79 Rectovaginal fistula has also been described and should be cautiously 
considered in female patients.77 
  
VII. Additional Applications 
 
The TAMIS platform continues to evolve, mostly because it provides easy access to the rectum and 
pelvis that allows it to be used for various additional applications. TAMIS has now been successfully 
performed with a variety of ports including other commercially available single-site ports60,63 and even a 
customized glove-port.64 Internationally, the further ports available are the KeyPort Flex (Richard Wolf, 
Knittlingen, Germany), the SSL (Single-Site Laparoscopic access system, Ethicon Endo-Surgery, Cincinnati, 
OH), and the Endorec® (Aspide Médical, LaTalaudière, France). With improved transanal visibility and 
exposure, TAMIS has been described for repair of rectourethral fistula, ligation of distal rectal 
hemorrhage, and removal of rectal foreign body.65 It is currently being effectively used as a new access 
channel for NOTES procedures, including transanal total mesorectal excision (taTME).66,67 This modality 




Despite a paucity of comparative data including long-term oncologic and functional data, TAMIS 
is a safe and effective means of local resection for benign and favorable early stage (T1) cancers 
following adequate workup for rectal lesions. It can be used as a conclusive biopsy for indeterminate T 
staged lesions in patients who are hesitant to undergo major resection with the intent to follow through 
with definitive treatment for T1 lesions exhibiting adverse pathologic features and T2 lesions. It may also 
be used as palliative resection for T3 cancers in patients medically unfit or unwilling to undergo an 
oncologic resection. A TAMIS resection can confirm complete pathologic response after neoadjuvant 
chemotherapy and radiation. The TAMIS platform is most advantageous for mid- and distal-rectal 
lesions that are unable to be removed colonoscopically, but should be used cautiously in the upper 
rectum, especially with full thickness resections. The TAMIS platform makes access for endoluminal 
surgery of the rectum straightforward, and expansion of its applications is expected to continue. 
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